retatrutide phase 2 trial weight loss 24.2% body lost at 48 weeks. Not by eating less. By burning more at rest. is a triple agonist: a single synthetic peptide that simultaneously engages three receptors — GLP-1R retatrutide weight loss phase 2

Retatrutide is being studied as a next-generation medication that targets three hormone pathways involved in appetite, metabolism, blood sugar regulation, and energy balance

It leads to gastrointestinal side effects

2024 PMID: 39226030

It is also important to note that semaglutide should not be used during breastfeeding, as stated in the SmPC, due to insufficient data on its excretion in human milk and potential effects on the infant

Step 3: Begin Your Weight Loss Journey There's no single best path to treatment

Patients must apply for this program and could receive full medication at no cost if approved and meet certain income requirements based on their state of residence